Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)

To search for a Maximum Tolerated Dose (MTD) for the combination of daratumumab and induction chemotherapy with Idarubicin and cytarabine or CPX-351 in patients with Acute Myeloblastic Leukemia (AML) of poor prognosis

Trial Details

NCT ID

NCT05749276

Phase

PHASE1

Sponsor

Nantes University Hospital

Status

RECRUITING

Cancer Type

Leukemia

Interventions

Darzalex

Locations (sample)

Nantes, France|47.21725,-1.55336

Key Eligibility Criteria

Age \>= 60 ans
Poor prognosis AML defined according to the following criteria:1. For first-line AML:intermediate or unfavorable risk according to ELN 2022 2.for R…
ECOG \<= 2
Patient eligible for intensive chemotherapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →